标签归档：phenyl

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 

STAT3-IN-7 是一种 Sorafenib 的衍生物，可有效抑制 STAT3 的磷酸化。STAT3-IN-7 通过依赖 SHP-1 的 STAT3 失活诱导细胞凋亡 (apoptosis)，不抑制激酶活性，并具有抗癌作用。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea Chemical Structure

CAS No. : 1313019-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects[1].

IC50 & Target[1]

p-STAT3

 

体外研究
(In Vitro)

STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 48 hours
Result: Demonstrated dose-dependent suppression of cell viability in all tested breast cancer cells.

Apoptosis Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Induced potent apoptotic activity.

Western Blot Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Showed downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines.

体内研究
(In Vivo)

STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells [1]
Dosage: 10 mg/kg
Administration: Oral gavage; daily; for 28 days
Result: Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.

分子量

431.80

Formula

C21H13ClF3N3O2
CAS 号

1313019-65-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chun-Yu Liu, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15(4):R63.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 

STAT3-IN-7 是一种 Sorafenib 的衍生物，可有效抑制 STAT3 的磷酸化。STAT3-IN-7 通过依赖 SHP-1 的 STAT3 失活诱导细胞凋亡 (apoptosis)，不抑制激酶活性，并具有抗癌作用。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea Chemical Structure

CAS No. : 1313019-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects[1].

IC50 & Target[1]

p-STAT3

 

体外研究
(In Vitro)

STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 48 hours
Result: Demonstrated dose-dependent suppression of cell viability in all tested breast cancer cells.

Apoptosis Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Induced potent apoptotic activity.

Western Blot Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Showed downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines.

体内研究
(In Vivo)

STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells [1]
Dosage: 10 mg/kg
Administration: Oral gavage; daily; for 28 days
Result: Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.

分子量

431.80

Formula

C21H13ClF3N3O2
CAS 号

1313019-65-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chun-Yu Liu, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15(4):R63.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 

STAT3-IN-7 是一种 Sorafenib 的衍生物，可有效抑制 STAT3 的磷酸化。STAT3-IN-7 通过依赖 SHP-1 的 STAT3 失活诱导细胞凋亡 (apoptosis)，不抑制激酶活性，并具有抗癌作用。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea Chemical Structure

CAS No. : 1313019-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects[1].

IC50 & Target[1]

p-STAT3

 

体外研究
(In Vitro)

STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 48 hours
Result: Demonstrated dose-dependent suppression of cell viability in all tested breast cancer cells.

Apoptosis Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Induced potent apoptotic activity.

Western Blot Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Showed downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines.

体内研究
(In Vivo)

STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells [1]
Dosage: 10 mg/kg
Administration: Oral gavage; daily; for 28 days
Result: Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.

分子量

431.80

Formula

C21H13ClF3N3O2
CAS 号

1313019-65-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chun-Yu Liu, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15(4):R63.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

4-methyl-6-phenyl-2H-pyranone对照品

发表于由
4-methyl-6-phenyl-2H-pyranone对照品

  【编号】：PR1815

  【产品名称】：4-methyl-6-phenyl-2H-pyranone对照品

  【规格】：10mg

  【用途】：

　　4-methyl-6-phenyl-2H-pyranone对照品

　　编号：PR1815
　　英文名称：4-methyl-6-phenyl-2H-pyranone
　　Cas 号: 4467-30-5
　　分 子 式：C12H10O2
　　分 子 量：186.21
　　植物来源：黄芩
　　纯度: 95%~99%
　　分析方法: HPLC-DAD or/and HPLC-ELSD
　　鉴定方法: 质谱（Mass）, 核磁（NMR）
　　包装: 棕色小玻璃瓶，标准包装10mg，20mg，50mg；可以按客户需求包装。
　　类别：上海金畔生物科技有限公司，中药对照品
　　作为标准品，对照品或者供研究用，不能直接用于人体。

3-Phenyl-1,2-dihydroacenaphthylene-1,2-diol

发表于由
3-Phenyl-1,2-dihydroacenaphthylene-1,2-diol

  【编号】：SPR03680

  【产品名称】：3-Phenyl-1,2-dihydroacenaphthylene-1,2-diol

  【规格】：10mg

  【用途】：

　　3-Phenyl-1,2-dihydroacenaphthylene-1,2-diol对照品

　　编号：SPR03680
　　英文名称：3-Phenyl-1,2-dihydroacenaphthylene-1,2-diol
　　CAS No.：193892-33-0
　　分 子 式：C18H14O2
　　分 子 量：262.308
　　包装: 棕色小玻璃瓶，按客户需求包装。
　　类别：上海金畔生物科技有限公司，中药对照品
　　作为标准品，对照品或者供研究用，不能直接用于人体。

3-Phenyl-1-(pyrrol-1-yl)propan-1-one

发表于由
3-Phenyl-1-(pyrrol-1-yl)propan-1-one

  【编号】：SPR02861

  【产品名称】：3-Phenyl-1-(pyrrol-1-yl)propan-1-one

  【规格】：10mg

  【用途】：

　　3-Phenyl-1-(pyrrol-1-yl)propan-1-one对照品

　　编号：SPR02861
　　英文名称：3-Phenyl-1-(pyrrol-1-yl)propan-1-one
　　CAS No.：112448-69-8
　　分 子 式：C13H13NO
　　分 子 量：199.253
　　包装: 棕色小玻璃瓶，按客户需求包装。
　　类别：上海金畔生物科技有限公司，中药对照品
　　作为标准品，对照品或者供研究用，不能直接用于人体。